EMA: CHMP Positive Opinion: Liraglutide STADA

EMA21 May 2026CHMP Positive Opinion● 6/10i

EMA: CHMP Positive Opinion: Liraglutide STADA

STADA Arzneimittel AG

CHMP issued a positive opinion for Liraglutide STADA on May 21, 2026, for type 2 diabetes treatment in adults, adolescents and children aged 10 years and above as adjunct to diet and exercise. This represents a generic marketing authorization application for liraglutide, expanding access to Novo Nordisk's established GLP-1 receptor agonist through STADA Arzneimittel AG. STADA gains entry into the competitive GLP-1 market with a biosimilar version of Victoza, potentially offering cost advantages in European markets where pricing pressure on incretin therapies continues to intensify.

Strategic Signal

STADA's liraglutide biosimilar will pressure Novo Nordisk's Victoza pricing across EU markets, accelerating the shift toward newer agents like semaglutide and tirzepatide in formulary positioning. European payers will likely leverage this competition to drive deeper discounts on first-generation GLP-1s while maintaining premium positioning for dual-mechanism agents. This follows the established biosimilar adoption pattern seen with insulin, where originator market share eroded 40-60% within two years of biosimilar launch in key EU markets.

GLP-1Type 2 diabetesPricing/accessSTADA Arzneimittel AG Novo Nordisk

Original Abstract

EMA action: CHMP Positive Opinion | Medicine: Liraglutide STADA | INN (active substance): liraglutide | Decision date: May 21, 2026 | Sponsor: STADA Arzneimittel AG | EMA product number: EMEA/H/C/006615 | Indication: Treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise | Geography: European Union (EMA / EC)

View original source ↗

Related signals

Strategic Signal

FDA1 Apr 2026New Drug Approval (NDA/BLA)High impact● 10/10i

FDA Approves Foundayo (Orforglipron) — New Drug Approval (NDA/BLA)

FDA approved orforglipron (Foundayo, Eli Lilly) for type 2 diabetes -- a once-daily oral small-molecule GLP-1 receptor agonist. Orforglipron is the first non-peptide oral GLP-1 approved in the US; oral semaglutide (Rybelsus, Novo Nordisk) has been approved for T2D since 2019 and expanded to obesity in January 2026. Unlike Rybelsus, orforglipron requires no fasting or water volume restrictions before dosing.

GLP-1Type 2 diabetesPricing/accessEli Lilly Novo Nordisk

Strategic Signal

Clinical Trial19 Mar 2026Phase 3High impact● 9/10i

Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-1)

Phase 3 SURMOUNT-1 tests once-weekly tirzepatide at three doses versus placebo in adults without type 2 diabetes who have obesity or are overweight with comorbidities. The randomized, double-blind trial targets 2,539 participants with primary efficacy assessment at 72 weeks. This represents tirzepatide's pivotal obesity trial against placebo, potentially supporting Eli Lilly's bid to compete directly with Wegovy in the non-diabetic obesity market. A prediabetes subgroup continues long-term to assess diabetes prevention.

Weight lossGLP-1Eli Lilly

Strategic Signal

Clinical Trial17 Apr 2026Phase 3High impact● 8/10i

A Phase 3, Open-Label Study of Once Daily LY3502970 Compared With Insulin Glargine in Adult Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Phase 3 open-label trial compared once-daily oral orforglipron versus insulin glargine in people with type 2 diabetes and obesity or overweight at increased cardiovascular risk. The study enrolled 2,749 participants with primary endpoint of time to first major adverse cardiovascular event, completed in March 2026. Eli Lilly is positioning orforglipron as a cardiovascular outcomes option in high-risk populations, directly competing with established insulin therapy in this indication. This represents the first cardiovascular outcomes trial for orforglipron following its April 2026 FDA approval for type 2 diabetes.

GLP-1Type 2 diabetesWeight lossCardiovascularEli Lilly

Strategic Signal

Clinical Trial13 Apr 2026Phase 3High impact● 8/10i

A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Retatrutide Compared to Tirzepatide in Adults Who Have Obesity

Eli Lilly is conducting a Phase 3 head-to-head trial comparing retatrutide versus tirzepatide in adults with obesity. The double-blind study targets 800 participants over 89 weeks with primary endpoint of percent body weight change, completing December 2026. This represents the first direct comparison between Eli Lilly's next-generation triple receptor agonist retatrutide and its approved dual agonist tirzepatide in obesity. The trial positions Eli Lilly to potentially establish superiority claims for retatrutide ahead of expected regulatory submissions.

GLP-1Weight lossDrug comparisonsEli Lilly